<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03546829</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 08517</org_study_id>
    <nct_id>NCT03546829</nct_id>
  </id_info>
  <brief_title>Randomized Pilot Trial of Antimicrobial Therapy and Stereotactic Body Radiation Therapy in Early-stage Non-small Cell Lung Cancer</brief_title>
  <official_title>Randomized Pilot Trial of Antimicrobial Therapy and Stereotactic Body Radiation Therapy in Early-stage Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if the addition of vancomycin to SBRT increases a Th1 immune response measured
      by cytokine expression (IFN gamma)
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Covid-19
  </why_stopped>
  <start_date type="Actual">April 24, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Th1 immune response measured by cytokine expression (IFN gamma).</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Early Stage Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1 - Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>125 mg, 4x daily for 5 weeks</description>
    <arm_group_label>Arm 1 - Experimental</arm_group_label>
    <arm_group_label>Arm 2 - Control Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation Therapy (SBRT)</intervention_name>
    <description>Patients planned to undergo SBRT to a lung lesion will be randomized to either vancomycin for 1 week before RT and for 1 month after start of RT,</description>
    <arm_group_label>Arm 1 - Experimental</arm_group_label>
    <arm_group_label>Arm 2 - Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is planned to receive Stereotactic Body Radiotherapy (SBRT) to a biopsy-proven
             NSCLC

          -  Age 18 years old or older

          -  Patient capable of giving informed consent

        Exclusion Criteria:

          -  Use of antibiotics, antifungal, antivirals or antiparasitics during the 4 weeks prior
             to registration

          -  Active infection with oral temperature &gt;100Â°F

          -  Use of corticosteroids, methotrexate or immunosuppressive drugs during the 4 weeks
             prior to registration

          -  Use of chemotherapy during the 4 weeks prior to radiotherapy or during radiotherapy.
             Chemotherapy cannot begin before the collection of the 30-day post treatment sample
             (S4).

          -  Documented history of HIV, HBV or HCV

          -  Chronic constipation (bowel movements less frequent than every other day)

          -  Active uncontrolled gastrointestinal disorders such as inflammatory bowel disease,
             moderate/severe irritable bowel syndrome, persistent, infectious gastroenteritis,
             colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium
             Difficile infection (within 2 years of lung cancer diagnosis) or Helicobacter Pylori
             infection (untreated)

          -  Major surgery of the GI tract, with the exception of cholecystectomy and appendectomy,
             in the past five years. Any major bowel resection at any time

          -  Patients on anti-diarrheal medications

          -  Patients on probiotics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abigail Berman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 23, 2018</study_first_submitted>
  <study_first_submitted_qc>May 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

